Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer

Some colorectal cancer patients respond well to treatment with anti-EGFR antibodies, however response is almost invariably followed by acquired resistance. Here, the authors show that patients with shorter responses acquireRAS mutations, while those relapsing later preferentially develop mutations i...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Beth O. Van Emburgh, Sabrina Arena, Giulia Siravegna, Luca Lazzari, Giovanni Crisafulli, Giorgio Corti, Benedetta Mussolin, Federica Baldi, Michela Buscarino, Alice Bartolini, Emanuele Valtorta, Joana Vidal, Beatriz Bellosillo, Giovanni Germano, Filippo Pietrantonio, Agostino Ponzetti, Joan Albanell, Salvatore Siena, Andrea Sartore-Bianchi, Federica Di Nicolantonio, Clara Montagut, Alberto Bardelli
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2016
Materias:	Science Q
Acceso en línea:	https://doaj.org/article/24cf071741ce4d09aa89b3a6aab76cd5
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:24cf071741ce4d09aa89b3a6aab76cd5
record_format	dspace
spelling	oai:doaj.org-article:24cf071741ce4d09aa89b3a6aab76cd52021-12-02T15:35:26ZAcquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer10.1038/ncomms136652041-1723https://doaj.org/article/24cf071741ce4d09aa89b3a6aab76cd52016-12-01T00:00:00Zhttps://doi.org/10.1038/ncomms13665https://doaj.org/toc/2041-1723Some colorectal cancer patients respond well to treatment with anti-EGFR antibodies, however response is almost invariably followed by acquired resistance. Here, the authors show that patients with shorter responses acquireRAS mutations, while those relapsing later preferentially develop mutations in the extracellular domain of EGFR.Beth O. Van EmburghSabrina ArenaGiulia SiravegnaLuca LazzariGiovanni CrisafulliGiorgio CortiBenedetta MussolinFederica BaldiMichela BuscarinoAlice BartoliniEmanuele ValtortaJoana VidalBeatriz BellosilloGiovanni GermanoFilippo PietrantonioAgostino PonzettiJoan AlbanellSalvatore SienaAndrea Sartore-BianchiFederica Di NicolantonioClara MontagutAlberto BardelliNature PortfolioarticleScienceQENNature Communications, Vol 7, Iss 1, Pp 1-9 (2016)
institution	DOAJ
collection	DOAJ
language	EN
topic	Science Q
spellingShingle	Science Q Beth O. Van Emburgh Sabrina Arena Giulia Siravegna Luca Lazzari Giovanni Crisafulli Giorgio Corti Benedetta Mussolin Federica Baldi Michela Buscarino Alice Bartolini Emanuele Valtorta Joana Vidal Beatriz Bellosillo Giovanni Germano Filippo Pietrantonio Agostino Ponzetti Joan Albanell Salvatore Siena Andrea Sartore-Bianchi Federica Di Nicolantonio Clara Montagut Alberto Bardelli Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer
description	Some colorectal cancer patients respond well to treatment with anti-EGFR antibodies, however response is almost invariably followed by acquired resistance. Here, the authors show that patients with shorter responses acquireRAS mutations, while those relapsing later preferentially develop mutations in the extracellular domain of EGFR.
format	article
author	Beth O. Van Emburgh Sabrina Arena Giulia Siravegna Luca Lazzari Giovanni Crisafulli Giorgio Corti Benedetta Mussolin Federica Baldi Michela Buscarino Alice Bartolini Emanuele Valtorta Joana Vidal Beatriz Bellosillo Giovanni Germano Filippo Pietrantonio Agostino Ponzetti Joan Albanell Salvatore Siena Andrea Sartore-Bianchi Federica Di Nicolantonio Clara Montagut Alberto Bardelli
author_facet	Beth O. Van Emburgh Sabrina Arena Giulia Siravegna Luca Lazzari Giovanni Crisafulli Giorgio Corti Benedetta Mussolin Federica Baldi Michela Buscarino Alice Bartolini Emanuele Valtorta Joana Vidal Beatriz Bellosillo Giovanni Germano Filippo Pietrantonio Agostino Ponzetti Joan Albanell Salvatore Siena Andrea Sartore-Bianchi Federica Di Nicolantonio Clara Montagut Alberto Bardelli
author_sort	Beth O. Van Emburgh
title	Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer
title_short	Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer
title_full	Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer
title_fullStr	Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer
title_full_unstemmed	Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer
title_sort	acquired ras or egfr mutations and duration of response to egfr blockade in colorectal cancer
publisher	Nature Portfolio
publishDate	2016
url	https://doaj.org/article/24cf071741ce4d09aa89b3a6aab76cd5
work_keys_str_mv	AT bethovanemburgh acquiredrasoregfrmutationsanddurationofresponsetoegfrblockadeincolorectalcancer AT sabrinaarena acquiredrasoregfrmutationsanddurationofresponsetoegfrblockadeincolorectalcancer AT giuliasiravegna acquiredrasoregfrmutationsanddurationofresponsetoegfrblockadeincolorectalcancer AT lucalazzari acquiredrasoregfrmutationsanddurationofresponsetoegfrblockadeincolorectalcancer AT giovannicrisafulli acquiredrasoregfrmutationsanddurationofresponsetoegfrblockadeincolorectalcancer AT giorgiocorti acquiredrasoregfrmutationsanddurationofresponsetoegfrblockadeincolorectalcancer AT benedettamussolin acquiredrasoregfrmutationsanddurationofresponsetoegfrblockadeincolorectalcancer AT federicabaldi acquiredrasoregfrmutationsanddurationofresponsetoegfrblockadeincolorectalcancer AT michelabuscarino acquiredrasoregfrmutationsanddurationofresponsetoegfrblockadeincolorectalcancer AT alicebartolini acquiredrasoregfrmutationsanddurationofresponsetoegfrblockadeincolorectalcancer AT emanuelevaltorta acquiredrasoregfrmutationsanddurationofresponsetoegfrblockadeincolorectalcancer AT joanavidal acquiredrasoregfrmutationsanddurationofresponsetoegfrblockadeincolorectalcancer AT beatrizbellosillo acquiredrasoregfrmutationsanddurationofresponsetoegfrblockadeincolorectalcancer AT giovannigermano acquiredrasoregfrmutationsanddurationofresponsetoegfrblockadeincolorectalcancer AT filippopietrantonio acquiredrasoregfrmutationsanddurationofresponsetoegfrblockadeincolorectalcancer AT agostinoponzetti acquiredrasoregfrmutationsanddurationofresponsetoegfrblockadeincolorectalcancer AT joanalbanell acquiredrasoregfrmutationsanddurationofresponsetoegfrblockadeincolorectalcancer AT salvatoresiena acquiredrasoregfrmutationsanddurationofresponsetoegfrblockadeincolorectalcancer AT andreasartorebianchi acquiredrasoregfrmutationsanddurationofresponsetoegfrblockadeincolorectalcancer AT federicadinicolantonio acquiredrasoregfrmutationsanddurationofresponsetoegfrblockadeincolorectalcancer AT claramontagut acquiredrasoregfrmutationsanddurationofresponsetoegfrblockadeincolorectalcancer AT albertobardelli acquiredrasoregfrmutationsanddurationofresponsetoegfrblockadeincolorectalcancer
_version_	1718386521934921728

Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer

Ejemplares similares